The biotech industry is experiencing a dynamic rebound, with investors refocusing on innovation after a period of cautious optimism. Despite macroeconomic challenges in recent years, 2024 saw the sector regain momentum in both venture funding and public offerings, especially across the United States and Europe. “The industry rebounded from broader economic challenges… The focus has […]
